March 25, 2013 / 7:17 AM / 4 years ago

AstraZeneca settles Crestor patent row with generics firms

LONDON, March 25 (Reuters) - AstraZeneca has settled a legal fight over its top-selling cholesterol drug Crestor with generics companies, protecting revenues in the all-important U.S. market until 2016.

Under the agreement, Watson and Egis concede that the Crestor substance patent is valid. The settlement allows Watson to begin selling a generic version of Crestor on May 2, 2016, at a fee to AstraZeneca of 39 percent of net sales, until the end of paediatric exclusivity on July 8, 2016.

AstraZeneca said on Monday its partner Shionogi was also a party to the settlement agreement.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below